Abstract
Hemophagocytic lymphohistiocytosis (HLH) is a rare and severe inflammatory disorder marked by abnormal cytotoxic T and natural killer cell activity, resulting in impaired clearance of pathogen, excessive cytokine production, and continued immune system activation. Soluble IL-2 receptor (sIL-2R or sCD25) is typically elevated in HLH and can serve as a marker of disease activity, although its role in the pathophysiology of the disease is unclear. Here we present a case of an adult patient with steroid-dependent HLH who was treated successfully with daclizumab, a monoclonal anti-CD25 antibody, allowing successful withdrawal of steroid therapy without an increase in symptoms.
| Original language | English |
|---|---|
| Pages (from-to) | 747-749 |
| Number of pages | 3 |
| Journal | American Journal of Hematology |
| Volume | 83 |
| Issue number | 9 |
| DOIs | |
| State | Published - Sep 2008 |
Keywords
- Adrenal Cortex Hormones/therapeutic use
- Antibodies, Monoclonal, Humanized
- Antibodies, Monoclonal/therapeutic use
- Antineoplastic Combined Chemotherapy Protocols/administration & dosage
- Biomarkers
- Cyclophosphamide/administration & dosage
- Cyclosporine/therapeutic use
- Daclizumab
- Doxorubicin/administration & dosage
- Ferritins/blood
- Humans
- Immunoglobulin G/therapeutic use
- Immunosuppressive Agents/therapeutic use
- Interleukin-2 Receptor alpha Subunit/antagonists & inhibitors
- Killer Cells, Natural/immunology
- Lymphohistiocytosis, Hemophagocytic/complications
- Lymphoma, Large-Cell, Anaplastic/complications
- Male
- Middle Aged
- Prednisone/administration & dosage
- Recurrence
- T-Lymphocyte Subsets/chemistry
- Vincristine/administration & dosage